FDA
7th January 2014

FDA Advisory Committee Roll Call – New Year Update!

Several committees saw the departure of standing members, with no replacements to note. The Anesthetic and Analgesic Drug Products Advisory Committee saw the departure of Michael R. Clark – increasing their vacancies to 2. The Dermatologic and Ophthalmic Drug Advisory Committee saw the departures of three of their members – raising the number of vacancies to 11.

FDA Advisory Committee Roll Call – New Year Update!

It’s may be a New Year, but there are only a few changes to the current drugs Advisory Committee rosters so far!

Several committees saw the departure of standing members, with no replacements to note. The Anesthetic and Analgesic Drug Products Advisory Committee saw the departure of Michael R. Clark – increasing their vacancies to 2. The Dermatologic and Ophthalmic Drug Advisory Committee saw the departures of three of their members – raising the number of vacancies to 11. Lastly the Pharmaceutical Science and Clinical Pharmacology Advisory committee also lost one member, bringing the number of vacancies to 17.

The Anti-infective Drugs Advisory Committee also has one more vacancy (bringing the total number to 2), as member Capt. Monica E. Parise, MD was moved into the Chair position. Dr. Parise is also the Chief of the Parasitic Diseases Branch, Division of Parasitic Diseases and Malaria, part of the CDC.

Lastly, the Gastrointestinal Drugs Advisory Committee (GIDAC) welcomed two new members, dropping the number of vacancies to zero. These two new members are:

  • Timothy O. Lipman, MD, expert in gastroenterology and clinical nutrition, is Emeritus Chief, GI-Hepatology-Nutrition Section at the Department of Veterans Affairs Medical Center in Washinton, DC.
  • Miriam Vos, MD, MSPH, expert in pediatric hepatology, is an Assistant Professor of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition at the Emory University School of Medicine.

Stay tuned for our next AdComm Roll Call Special where we will put the spotlight on one of the drug Advisory Committees!

ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact info@innovativescience.net

Interested in learning about ISS’ expert approach to Advisory Committee Meetings? Click below in order to find out for yourself!

Generic Blog CTA for Ad Comm Approach

Recent Related Articles

Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission
01 July 2020
Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission

Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more

Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices
25 June 2020
Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices

FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more

NDA vs. OTC Monograph: Which Pathway is Right for You?
22 June 2020
NDA vs. OTC Monograph: Which Pathway is Right for You?

One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more

4 Problems Importing Rapid Antibody Tests for Coronavirus
19 June 2020
4 Problems Importing Rapid Antibody Tests for Coronavirus

US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more

Let’s work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us